Varenicline use is associated with a lower risk of ADRD among older adults receiving smoking cessation therapy and the value of explainable AI-guided approaches to drug repurposing is underscored.
Abstract
Objective: Effective strategies to prevent Alzheimer's disease and related dementias (ADRD) are limited. Implementing our Medication-Wide Association Study (MWAS+), we highlighted varenicline as a candidate. This study evaluated the association between varenicline use and risk of ADRD relative to nicotine replacement therapy (NRT). Methods: Using the All of Us Research Database, we identified adults aged 50 years or older with available lifestyle survey responses regarding tobacco use history who initiated smoking cessation therapy with either varenicline or NRT between 2006 and 2023. We limited our cohort to incident monotherapy users and designated the index date as the first prescription. Individuals with baseline ADRD or no follow-up were excluded. Baseline characteristics included demographics, comorbidities, BMI, and prior medication exposures. Outcomes were incident ADRD and a composite outcome of ADRD or death. Findings: The cohort consisted of 9,584 individuals (1,801 varenicline users and 7,783 NRT users). After propensity score matching, there were 1,758 individuals in each group with balanced baseline characteristics. Varenicline use was associated with a reduced risk of ADRD (HR 0.516, 95% CI: 0.353-0.754) and the composite outcome ADRD or death (HR 0.657, 95% CI: 0.501-0.861). Kaplan-Meier curves also demonstrated varenicline's sustained benefits through the study period. Implications: Varenicline use is associated with a lower risk of ADRD among older adults receiving smoking cessation therapy. Further investigation of varenicline as a potential strategy for ADRD prevention is warranted. These findings underscored the value of explainable AI-guided approaches to drug repurposing.
BACKGROUND
Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population-level evidence on its effect on PD risk is lacking.
OBJECTIVES
To compare the risk of incident PD among UDCA initiators versus matched non-i...
C. Ju, A. Schrag, Camille B. Carroll et al.· Movement Disorders· 0 citations
Background Lithium and valproate are widely prescribed mood stabilizers, but their comparative long-term associations with mortality and dementia remain uncertain. We compared the risks of all-cause mortality and incident dementia among adults initiating lithium or valproate using a large multinational electronic healt...
Da-Han Hou, Yu-Hsien Wu, Ming-Ju Wu et al.· Frontiers in Neurology· 0 citations
Objective To evaluate the associations between commonly used antidiabetic regimens and incidence of mild cognitive disorder, Alzheimer disease, and vascular dementia in adults with type 2 diabetes. Design, setting, and participants This retrospective cohort study used the TriNetX US Collaborative Network of electronic...
A. B. Nasir, Yassine Kilani, Mohammad Aldiabat et al.· PLoS ONE· 0 citations
OBJECTIVES
To examine treatment duration of oral and transdermal cholinesterase inhibitor formulations in older adults with severe Alzheimer's disease (AD) in routine clinical practice.
DESIGN
Retrospective population-based cohort study.
SETTING AND PARTICIPANTS
Linked medical and long-term care insurance claims da...
So Sato, Y. Sasabuchi, H. Yamana et al.· Journal of the American Medi...· 0 citations
Abstract Objective Given the persistent absence of direct head-to-head trials, this study aimed to evaluate the comparative efficacy, safety, and cost-effectiveness of rasagiline versus selegiline as early-stage monotherapy for Parkinson’s disease (PD), informing clinical selection and healthcare policies in China. Met...
Symptomatic treatment remains the cornerstone of therapeutic management in frontotemporal dementia (FTD), as disease-modifying therapies are currently unavailable. However, several medications originally developed for other neuropsychiatric conditions may represent potentially harmful medications (PHMs) in FTD. This st...
L. Botton, F. J. Lazzaretti, Carlos Lokschin et al.· Frontiers in Neurology· 0 citations
Related blog posts
Microsoft Research Blog· microsoft.comNov 16, 2026
AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.
At ICSOB 2026 in Gothenburg, we presented TenderIntell, our work on multi-agent support for tendering. This post looks back at the conference, the idea behind a panel of three AI reviewers who score each proposal independently, and why evaluating agents reliably is the question we keep coming back to. The post TenderIntell at ICSOB 2026: Three Days in Gothenburg appeared first on GPT-Lab.
MIT News · Artificial Intelligence· news.mit.eduNov 13, 2026
Founded by Anthony Jules ’92, SM ’92 and Professor Emeritus Rodney Brooks, Robust AI’s robots are designed to collaborate with humans in factories and warehouses.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.